Molecular docking analysis of a secondary metabolite with the glycoprotein receptors of HSV 1 and HSV 2

Natarajan Saran\textsuperscript{1,2}, Balaiyah Anandharaj\textsuperscript{2}, Giridharan Bupesh\textsuperscript{1,3,*}, Sakthivel Vasanth\textsuperscript{3}, Joseph Pinto Jasmine Beulah\textsuperscript{3}, Vellingiri Balachandar\textsuperscript{4}

\textsuperscript{1}Department of Virology, King Institute of Preventive Medicine and Research, Chennai, India; \textsuperscript{2}Department of Microbiology, M.R. Government College, Mannargudi, India; \textsuperscript{3}Research & Development Wing, Sree Balaji Medical College and Hospital (SBMCH), Bharath University, BIHER, Chrompet, Chennai - 600044, Tamil Nadu, India; \textsuperscript{4}Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore Tamil Nadu, India; Dr. G. Bupesh - E-mail: bupeshgiri55@gmail.com; Phone +91 8012405965; *Corresponding author.

Received October 18, 2019; Revised December 18, 2019; Accepted December 25, 2019; Published December 31, 2019

DOI: 10.6026/97320630015887

Abstract: Herpes simplex viruses (HSV) are alpha herpes viruses, which causes life-threatening illness. Therefore, it is of interest to design and develop potential drugs to treat HSV infections. We show the optimal molecular docking properties of a secondary metabolite (3, 7, 11, 15 tetra methyl-2-2-hexadecen-1-ol) with the glycoprotein receptors of HSV1 and HSV 2 for further consideration.

Keywords: Herpes simplex virus 1 & 2, glycoprotein, PHYTOL, ADMET properties, drug likeliness

Background: Herpes simplex virus 1 and 2 are classified in the family of an alpha herpes virus, which causes mucal lesions in the oral and reproductive organs. Globally 1.6 million new cases of HSV were reported every year, where 22% of adults in USA show antibody for the virus [1, 2]. Both HSV 1 and 2 are highly contagious pathogens causing recurrent lesions. Herpes infections are caused by entry in to cells to trigger the envelope film or cell-cell combination [3]. There are four major viral envelope glycoproteins gD, gE, gB, and gH which help in inducing infection in the host by entry and replication in the cells. Glycoprotein D (gD) is the receptor protein which binds activates the other heterodimer such as gH/gL to elicit gB to mediate the fusion of viral and host cellular membranes. Virus entries [4] lead cause recurrent lesions. Therefore, the glycoproteins are key molecular machinery with highly conserved common domains as target for the novel discovery of antitherpes drugs. Ethanolic, chloroform and aqueous extracts of Justicae adothoda leaves were evaluated for the antiviral activity. Among the extracts, the ethanolic extract of Justicae adothoda revealed a promising antiviral activity. Further, the extracts were identified through analytical techniques such as gas chromatography, mass spectra and high-pressure thin layer chromatography. The GCMS chromatogram of ethanolic extract depicts the presence of active compound PhytaL. PhytaL is a naturally occurring organic compound belonging to the member of diterpenoids. It is a long chain unsaturated acyclic alcohols, which exhibits wide range of biological activities. It is used as aroma compound with prospective candidate for a wide range of applications in the chemotherapeutics and other biotechnological industry. PhytaL exerts many medicinal properties such as antimicrobial, anti-inflammatory, anti nociceptive, anxiolytic, immuno modulating, metabolism modulating, antioxidant, autophagy, and apoptosis inducing activity and
cytotoxicity effects. Therefore, it is of interest to design and develop potential drugs to treat HSV infections. We show the optimal molecular docking properties of a secondary metabolite (3,7,11,15 tetra methyl-2-2-hexadecen-1-ol) with the glycoprotein receptors of HSV1 and HSV 2 for further consideration.

Methodology:
Preparation and optimization of receptors and ligands:
The 3-dimensional glycoprotein-D, E structures of HSV 1 & 2 were downloaded from the protein data bank (PDB) Research Collaboration for Structural Biology (RCSB) [5] files with PDB IDs 2C36, 3U82, 2GIY and 4MYV. It was optimized using Discovery Studio and then exported into docking tools (MT, Ligplot and Autodock). The receptor protein was analysed using side chain packing, energy minimization and optimization using protein preparation tools. The hydrogen atoms were added, bond orders were assigned and waters molecules were removed from the exterior to 5Å site. The P ionization, optimization, energy minimization was done for the 3D geometry of targeted receptors. The ligands were prepared using ligplot and docking was done using Auto dock. 3-D structures of the ligands were optimized as described else were Banks et al. [6].

The molecular docking framework for HSV-1 protein (PDB: 2K15) shown was created using Autodock as described elsewhere [7]. Discovery studio was used for visualization of the glycoproteins of HSV 1 and 2 proteins with data corresponding to PDB ID: 2C36, 3U82, 2GIY and 4MYV. The ligand was optimized using ligplot. The van der Waals (vdW) scaling factor fractional increment was selected as 0.85, 0.25, respectively for ligand atoms. The docking scores were calculated using atomic contact energy, energy transformation and score values [8]. ADMET properties of the phytal ligand were calculated using PreADMET/Tox tools [9]. The parameters such as SK log5pure, SK log5buffer, SK log P-value and SK logD-value for Cytochrome P450 families CYP-3A4-substrate, CYP-3A4-inhibition, CYP-2D6-substrate, CYP-2D6-inhibition, CYP-2C9-inhibition and CYP-2C19-inhibition, Plasma protein binding, Blood brain wall penetration, Skin permeability, human intestinal absorption, Cellular permeability by Caco2 and cell lines (MDCK) were calculated using PreADMET/Tox tools.

Molecular properties and drug likeliness prediction:
Molecular properties and drug likeliness were calculated using molinspiration (https://www.molinspiration.com/). This tool predicts the parameters such as LogP, Total Polar surface Area (TPSA), molecular volume and Rule 5 properties [9]. The log P-value is calculated on the basis of contribution by octanol/water coefficient. TPSA is the sub-atomic polar surface region description of the compound. This parameter determines the drug absorption in intestine, bioavailability, permeability and penetration. The number of rotatable bonds reflects the oral bioavailability of drugs based on the lone pair non-ring bond with non-terminal heavy atoms. The TPSA is calculated as described elsewhere [10]. Drug likeliness of compounds was assessed using the prediction tool Molinspiration.

Rule of 5 properties:
Atomic descriptors used in Lipinski "Standard Rule of 5 properties" were described elsewhere [2]. It states that most "tranquilize like" particles have logP <= 5, sub-atomic weight <= 500, number of hydrogen bond acceptors <= 10, and number of hydrogen bond contributors <= 5. Atoms disregarding more than one of these guidelines may have issues with bioavailability. The standard is classified as "Rule of 5".

Number of rotatable bonds (nrotb):
This topological parameter is related to sub-atomic adaptability. It is a descriptor of oral bioavailability of drug like compounds [3]. Rotatable bond is characterized as a single non-ring bond that is limited to non-terminal overwhelming (i.e., non-hydrogen) molecule. Amide C-N bonds are not considered in light of their high rotational vitality barrier.

Results:
The binding of the compound phytal (3,7,11,15 tetra methyl-2-2-hexadecen-1-ol) with the glycoprotein envelope proteins D and E of HSV 1 and 2 is studied in this analysis with ADMET evaluations. Data on the active compounds of Justicia adathoda were known available from Gas chromatography and Mass spectroscopy analysis. The ligand structure is generated using ligplot (Figure 1). The crystal structures of receptors (Figure 2) were optimized using Discovery studio and their binding pockets were identified using molecular tools supported by supercomputing facilities. The docking between phytal and the HSV 1 and 2 glycoprotein receptors gD and gE were completed using AutoDock as shown in Figure 3 and Figure 4 with molecular binding features summarized in Table 1, Table 2 and Table 3. The ADMET properties of the protein-ligand complex are given in Table 4 and Figure 5.
Table 1: Docking of Phytal with Glycoprotein receptors of HSV virus

| HSV-1 & 2 receptors with phytal | Score in K/cal | Area | ACE | Ligand Transformation |
|--------------------------------|----------------|------|-----|----------------------|
| Glycoprotein HSV-1 gD (PDB.ID: 2C36) | 3632 | 414.90 | -64.67 | 2.34 -1.37 1.38 61.90 60.48 109.22 |
| Glycoprotein HSV-2 gD (PDB.ID: 4MYV) | 3874 | 457.80 | -76.89 | 2.81 -0.18 1.47 2.63 -21.54 11.83 |
| Glycoprotein HSV-1 gE (PDB.ID: 3U82) | 3744 | 450.90 | -57.76 | -0.33 0.98 2.36 -34.91 56.82 -13.79 |

Table 2: Cavities in HSV glycoproteins with active amino acid residues

| S. No | HSV glycoprotein | Cavity point | Cavity volume | Catalytic amino acid residues |
|-------|------------------|--------------|---------------|-------------------------------|
| 1     | gD HSV-1 PDB.ID:2C36 | 43.076 69.135 4.848 | 599 | PRO 190, GLU 191, ALA 192, LEU 194, PHE 195, SER 196, PRO 197 |
| 2     | gD HSV-1 PDB.ID:2GIY | 37.725 53.064 137.165 | 560 | VAL 309, TYR 310 & 311, VAL 313, ILE 432, THR 501, SER 502, THR 503, LEU 504 |
| 3     | gD HSV-1 PDB.ID:3U82 | 5.821 -13.022 -3.323 | 198 | Tyr 116, ALA 121, SER 123, GLU 124, ASP 125, ASN 126, GLY 128, PHE 129, LEU 130 |
| 4     | gD HSV-2 PDB.ID:4MYV | -0.809 -3.680 25.045 | 375 | SER 7, 39; LEU 8, 129, 131; GLU 9, 139; ASP 10; PRO 11, 14, 15, 73; VAL 76; PHE 12; GLN 13, 142 ILE 19, 74, 140, LYS 133 THR 60, 127, 138; MET 66 TYR 128, 162; ASN 112 |

Figure 2: 3D structure of envelope glycoprotein from HSV-1 represented using ribbon form and CPK depiction is used for predicted active sites. (a) glycoprotein HSV gD with active sites (PDB ID: 2C36); (b) C-terminal domain of the HSV-1 gE ecto domain with active sites (PDB ID: 2GIY); (c) glycoprotein D with active sites (PDB ID: 3U82); (d) gD HSV-2 with active sites (PDB ID: 4MYV).
Discussion:
Glycoproteins are the key molecular targets of HSV. There are 11 glycoproteins on the HSV lipid membrane. It is known that 5 among them 5 are linked with cell entry: gB, gC, gD, and the heterodimer gH/gL [3]. HSV infection starts by the effective adherence of the viral envelope glycoprotein-D (gD) to cell surface receptors. These glycoproteins are soluble, truncated ectodomain that exists monomer and in complex state with the ectodomain of

Table 4: ADME properties of the Phytal

| S. No | ADME parameters | Value       |
|-------|----------------|-------------|
| 1     | SK logS-pure   | -6.821510   |
| 2     | SK logS-buffer | -6.642220   |
| 3     | SK logP-value  | 7.305270    |
| 4     | SK logD-value  | 7.305270    |
| 5     | Skin-Permeability | -0.521653  |
| 6     | Pure water-solubility-mg-L | 0.0444226   |
| 7     | Plasma Protein Binding | 100.000000  |
| 8     | Pgp-inhibition | Inhibitor   |
| 9     | MDCK           | 65.504*     |
| 10    | HIA            | 100.000000  |
| 11    | CYP-3A4-substrate | Substrate  |
| 12    | CYP-3A4-inhibition | Inhibitor  |
| 13    | CYP-2D6-substrate | Non       |
| 14    | CYP-2D6-inhibition | Non      |
| 15    | CYP-2C9-inhibition | Inhibitor |
| 16    | CYP-2C19-inhibition | Inhibitor |
| 17    | Caco2          | 41.2956     |
| 18    | Buffer solubility-mg-L | 0.0671265   |
| 19    | BBB            | 19.6882     |

Table 3: Bioactivity score of ligands

| S. No | MOLINSPIRATION bioactivity     | Score |
|-------|--------------------------------|-------|
| 1     | GPCR LIGAND                    | -0.03 |
| 2     | ION CHANNEL MODULATOR         | -0.01 |
| 3     | KINASE INHIBITOR              | -0.30 |
| 4     | NUCLEAR RECEPTOR LIGAND       | 0.23  |
| 5     | PROTEASE INHIBITOR            | 0.24  |
| 6     | ENZYME INHIBITOR              | 0.18  |

Figure 3: Molecular docking interaction of phytal with the glycoprotein receptors

Figure 4: The binding site interaction shown using Discovery Studio

Discussion:
Glycoproteins are the key molecular targets of HSV. There are 11 glycoproteins on the HSV lipid membrane. It is known that 5 among them 5 are linked with cell entry: gB, gC, gD, and the heterodimer gH/gL [3]. HSV infection starts by the effective adherence of the viral envelope glycoprotein-D (gD) to cell surface receptors. These glycoproteins are soluble, truncated ectodomain that exists monomer and in complex state with the ectodomain of
its cell receptor HveA. Glycoproteins D have a conceivable restricting locale of receptor named gD receptor. The gD receptor ties with the 3-O-sulfonated heparan sulfate. Suddenly, the structures uncover a V-like immunoglobulin (Ig) crease at the center of gD that is firmly identified with cell attachment atoms and flanked by enormous N-and C-terminal extensions. The receptor adhering fragment of gD, a N-terminal barrette, found adaptable, proposing that a conformational change going with restricting may be a piece of the viral entry mechanism. gD is an objective for both the humoral and cell invulnerable reaction of the host. An HSV-2 subunit vaccine containing a soluble ectodomain of gD is in clinical trials in humans (gD-1 and gD-2 are 85% identical in amino acid sequence).

Three classes of receptors for HSV gD have been depicted. HveA (herpesvirus entry mediator A also called HVEM and TNFRSF14) is a member of the tumor necrosis factor receptor superfamily [11]. It is expressed on activated lymphocytes where it intercedes HSV entry [12]. The cellular function of HveA is to bind the TNF-like ligands. It has been reported that HSV-infected cytotoxic lymphocytes (CTL) rapidly eliminates to other T cells (“fratricide”) and speculated that infection of activated CTLs might provide the virus with a mechanism to evade host immunity. The class-II receptors including HveC immunoglobulin (Ig) also termed as nectin-1 superfamily members with one V-like and two C-like Ig domains. These proteins are functioned as homophilic adhesion molecules on the surface of neuronal and epithelial cells. The class-III receptors are heparan sulfate with 3-O-sulfonated derivatives, which result from D-glucosaminyl-3-O-sulfotransferase-3 alteration of heparan sulfate. The biological consequences of these receptors are still in evaluation. Glycoprotein E is present on the cellular surface of the envelope protein. Glycoproteins E encoded by the gene US8 and have a molecular mass of 80Kda. The glycoprotein E has affinity for the frequent resolution of IgG. It is also known that the binding of IgG inversed the occurrence of glycoprotein I [3].

gD of HSV-1 is a glycoprotein with 369 residues with an N-terminal ectodomain of 316 residues having three N-linked oligosaccharide attachment sites. The receptor has six cysteines residues, which forms 3 disulfide bonds between Cys 66-189, Cys 106-202, and Cys 118-127. Ectodomains of gD truncated residues 285 (gD285) or 275 (gD275) inhibits infection and bind to receptors in vitro 100 times better than a longer form gD306. Hence, we describe the optimal molecular docking properties of a secondary metabolite (3, 7, 11, 15 tetra methyl-2-2-hexadecen-1-ol) with the glycoprotein receptors of HSV1 and HSV 2 for further consideration. Glycoprotein D is encoded by the gene US6 and in plays a chief role in antigenic determinant in the HSV-1 viral envelope. The glycoprotein D in the HSV-1 viral envelop undergo frequent mutation for adherence of viral host cell interaction. The mutation in the glycoprotein D (gID) is unable to penetrate the host cell membrane for the establishment of infection in the host.

Conclusion:
We report the optimal molecular docking properties of a secondary metabolite (3, 7, 11, 15 tetra methyl-2-2-hexadecen-1-ol) with the glycoprotein receptors of HSV 1 and HSV 2 for further consideration.

Acknowledgement:
The open access charge for this article is partially supported by Biomedical Informatics (P) Ltd.
References:

[1] Fleming DT et al. N Engl J Med 1997 337:1105. [PMID: 9329932]
[2] Armstrong GL et al. Am J Epidemiol 2001 153:912. [PMID: 11323323]
[3] Spear PG & Longnecker R J Virol 2003 77:10179. [PMID: 12970403]
[4] Lipinski CA et al. Adv Drug Deliv Rev 2001 46:3. [PMID: 11259830]
[5] Rose PW et al. Nucleic Acids Res 2016 45:D271. [PMID: 27794042]
[6] Banks JL et al. J Comput Chem 2005 26:1752. [PMID: 16211539]
[7] Friesner RA et al. J Med Chem 2006 49:6177. [PMID: 17034125]
[8] Liu YJ et al. Mol Med Rep 2013 8:1106. [PMID: 23982123]
[9] Tripathi A et al. Toxicol Rep 2019 6:253. [PMID: 30911468]
[10] Ertl P et al. J Med Chem 2000 43:3714. [PMID: 11020286]
[11] Veber DF et al. J Med Chem 2002 45:2615. [PMID: 12036371]
[12] Heldwein EE & Krummenacher C, Cell Mol Life Sci 2008 65:1653. [PMID: 18351291]

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
